Advana Science

Advana Science is a biotechnology company focused on developing disease-modifying treatments for Alzheimer's disease and related neurodegenerative conditions. The company's primary approach utilizes "peptoids," which are synthetic, stable mimics of peptides designed to interfere with the misfolding and aggregation of amyloid-beta and tau proteins. Founded on research from the NYU School of Medicine, Advana Science aimed to target the toxic oligomeric species that drive neuronal damage. By utilizing protease-resistant molecules, the company sought to overcome the stability issues typically associated with peptide-based therapeutics. Although the company reached the pre-clinical stage with its lead candidates, it is currently considered inactive.